Annual report pursuant to Section 13 and 15(d)

Schedule of Stock Option Activity (Details)

v3.23.1
Schedule of Stock Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]      
Number of Options, Beginning Balance 464,021 151,147  
Weighted average exercise price, Beginning Balance $ 20.95 $ 9.10  
Weighted average remaining contractual term, Ending Balance 7 years 6 months 8 years 7 months 6 days 8 years 8 months 12 days
Number of Options, Granted 148,855 307,988  
Weighted average exercise price, Granted $ 5.02 $ 21.05  
Number of Options, StemoniX options exchanged for Vyant Bio options   (136,276)  
Weighted average exercise price, StemoniX options exchanged for Vyant Bio options   $ 9.20  
Number of Options, Vyant Bio options issued to StemoniX option holders   174,652  
Weighted average exercise price, Vyant Bio options issued to StemoniX option holders   $ 7.20  
Number of Options, assumed in Merger   11,168  
Weighted average exercise price, Options assumed in Merger   $ 229.75  
Number of Options, Exercised (1,034) (7,419)  
Weighted average exercise price, Exercised $ 4.80 $ 6.05  
Number of Options, Forfeited (141,306) (34,462)  
Weighted average exercise price, Forfeited $ 17.64 $ 18.45  
Number of Options, Expired (42,235) (2,777)  
Weighted average exercise price, Expired $ 36.33 $ 9.60  
Number of Options, Ending Balance 428,301 464,021 151,147
Weighted average exercise price, Ending Balance $ 14.97 $ 20.95 $ 9.10
Number of Options, Exercisable 232,175 127,119  
Weighted average exercise price, Exercisable $ 18.18 $ 27.90  
Weighted average remaining contractual term, Exercisable 6 years 4 months 24 days 7 years 1 month 6 days